Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

FM Nirmala Sitharaman to push biopharma, semiconductor missions in Norway

February 16, 2026 4 min read International Relations Science & Technology Economics GS3 GS2
On This Page ▼

What Happened

  • Finance Minister Nirmala Sitharaman undertook a visit to North America to promote two flagship manufacturing missions announced in Union Budget 2026: Biopharma Shakti and India Semiconductor Mission 2.0.
  • The diplomatic outreach sought to attract foreign investment, technology partnerships, and market access for these sectors, positioning India as a reliable global manufacturing hub.
  • Biopharma Shakti is a five-year, ₹10,000 crore programme aimed at boosting domestic production of biologics and biosimilars and establishing India as a global biopharma hub.
  • India Semiconductor Mission 2.0 (ISM 2.0) was announced with a revised outlay of ₹40,000 crore for the Electronics Components Manufacturing Scheme, focused on semiconductor equipment manufacturing, domestic IP development, and supply chain integration.
  • The North America visit targeted the US — India's largest trading partner and a key technology and capital source — at a time when India has also signed a framework for an interim trade agreement with the US (February 7, 2026).

Static Topic Bridges

India's Semiconductor Mission and Industrial Policy

Semiconductors — the integrated circuits that power virtually every modern electronic device — have emerged as a defining arena of strategic competition between major powers. India's original India Semiconductor Mission (ISM) was launched in 2021 with a ₹76,000 crore incentive package to attract chip manufacturing to India.

  • ISM 2.0, announced in Union Budget 2026-27, expands the focus beyond chip fabrication to include semiconductor equipment manufacturing, domestic materials supply, and full-stack Indian semiconductor intellectual property (IP) design.
  • The Electronics Components Manufacturing Scheme (ECMS) has been enhanced to ₹40,000 crore to capitalise on supply chain diversification away from China.
  • India's first commercial semiconductor fab is being established in Dholera (Gujarat) by Tata Electronics in partnership with Taiwan's Powerchip Semiconductor Manufacturing Corporation (PSMC), targeting 28nm chips.
  • A separate fab by CG Power (in collaboration with Japan's Renesas and Thailand's Stars Microelectronics) is planned in Sanand, Gujarat.
  • ISM 2.0 provides capital subsidies of 15–25% for semiconductor equipment manufacturing, reducing investment burden for companies entering the sector.
  • 24 semiconductor design startups are already supported under the scheme, with ~₹430 crore in venture capital attracted.

Connection to this news: The FM's North America outreach is aimed squarely at persuading American technology firms — facing supply chain pressure to diversify away from Chinese manufacturing — to choose India as a semiconductor partner and investment destination.

Biopharma Shakti and India's Pharmaceutical Sector

India is the world's largest supplier of generic medicines by volume, supplying approximately 20% of global generic drug exports. However, India has historically depended on China for Active Pharmaceutical Ingredients (APIs) — a dependence exposed starkly during the COVID-19 pandemic. Biopharma Shakti targets a new frontier: high-value biologics and biosimilars.

  • Biologics are medicines derived from biological sources (proteins, antibodies, living cells) rather than chemical synthesis — they include insulin, monoclonal antibodies, and cancer immunotherapies.
  • Biosimilars are near-identical copies of reference biologics whose patents have expired; they offer significant cost savings for healthcare systems globally.
  • India currently has a growing biosimilars industry but lacks large-scale domestic biomanufacturing infrastructure; Biopharma Shakti aims to bridge this gap with ₹10,000 crore over five years.
  • The Indian pharmaceutical industry is worth approximately $50 billion (2025) and is the largest supplier to the US generic drug market, supplying ~40% of US generic prescriptions.
  • The PLI (Production Linked Incentive) scheme for pharmaceuticals — worth ₹15,000 crore — already incentivises API and formulations manufacturing; Biopharma Shakti complements this for the biologics segment.

Connection to this news: The FM's North America pitch on biopharma targets US healthcare firms and government purchasers (including Medicare/Medicaid) who are under political pressure to reduce drug costs — India's biosimilar manufacturing could serve as a cost-effective partner.

India's Free Trade Agreement Strategy and Export Competitiveness

India's approach to trade liberalisation has historically been cautious, but 2025 marked a turning point with the signing of the India-UK CETA (July 24, 2025) — India's first FTA with a G7 nation — and further agreements with Oman, New Zealand, and a framework accord with the US.

  • The India-UK CETA (Comprehensive Economic and Trade Agreement), signed July 24, 2025, grants 99% of Indian exports duty-free access to the UK, covering textiles, pharmaceuticals, gems, marine products, and IT services.
  • UK tariffs on Indian pharmaceutical exports are being eliminated, while India gains fast-track market access with mutual recognition of Good Manufacturing Practices — directly relevant to biopharma.
  • For semiconductors, FTAs help by reducing input tariffs on equipment and components, enabling Indian fabs to source globally competitive inputs more cheaply.
  • India's export target is $500+ billion annually by 2030 — up from approximately $437 billion in 2024-25 — driven partly by FTA-enabled market access.

Connection to this news: The FM's North America visit combines FTA diplomacy (the ongoing India-US trade framework) with sectoral mission promotion, recognising that market access agreements and investment attraction are mutually reinforcing for manufacturing sectors like semiconductors and biopharma.

Key Facts & Data

  • Biopharma Shakti: ₹10,000 crore over five years for biologics and biosimilars manufacturing
  • India Semiconductor Mission 2.0: announced in Union Budget 2026; Electronics Components Manufacturing Scheme expanded to ₹40,000 crore
  • ISM 2.0 focus: semiconductor equipment manufacturing, domestic IP, supply chain integration
  • India-UK CETA signed: July 24, 2025; 99% of Indian exports to UK duty-free
  • India-US interim trade framework: announced February 7, 2026
  • India's pharma industry value: ~$50 billion; supplies ~40% of US generic prescriptions
  • Tata Electronics-PSMC semiconductor fab at Dholera, Gujarat: targeting 28nm chips
  • ISM capital subsidies: 15–25% for semiconductor equipment manufacturers
  • India's export target: $500+ billion/year by 2030
  • PLI scheme for pharmaceuticals: ₹15,000 crore (existing; Biopharma Shakti is additional)